GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (FRA:TGNA) » Definitions » EV-to-FCF

Transgene (FRA:TGNA) EV-to-FCF : -2.09 (As of Dec. 14, 2024)


View and export this data going back to . Start your Free Trial

What is Transgene EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Transgene's Enterprise Value is €81.08 Mil. Transgene's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-38.87 Mil. Therefore, Transgene's EV-to-FCF for today is -2.09.

The historical rank and industry rank for Transgene's EV-to-FCF or its related term are showing as below:

FRA:TGNA' s EV-to-FCF Range Over the Past 10 Years
Min: -8.52   Med: -4.8   Max: -1.13
Current: -2.09

During the past 13 years, the highest EV-to-FCF of Transgene was -1.13. The lowest was -8.52. And the median was -4.80.

FRA:TGNA's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs FRA:TGNA: -2.09

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Transgene's stock price is €0.716. Transgene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.220. Therefore, Transgene's PE Ratio (TTM) for today is At Loss.


Transgene EV-to-FCF Historical Data

The historical data trend for Transgene's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene EV-to-FCF Chart

Transgene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.24 -3.96 -7.62 -6.49 -3.31

Transgene Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -6.49 - -3.31 -

Competitive Comparison of Transgene's EV-to-FCF

For the Biotechnology subindustry, Transgene's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transgene's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Transgene's EV-to-FCF falls into.



Transgene EV-to-FCF Calculation

Transgene's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=81.080/-38.872
=-2.09

Transgene's current Enterprise Value is €81.08 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Transgene's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-38.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Transgene  (FRA:TGNA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Transgene's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.716/-0.220
=At Loss

Transgene's share price for today is €0.716.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Transgene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.220.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Transgene EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Transgene's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Transgene Business Description

Traded in Other Exchanges
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, FRA, 67400
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.